review
summar
literatur
data
develop
drug
base
natur
synthet
highpolymer
doublestrand
rna
dsrna
antivir
immunoadjuv
antitumor
properti
special
attent
paid
cell
receptor
respond
exogen
dsrna
pathway
dsrnadepend
antivir
reaction
abil
dsrna
inhibit
growth
induc
apoptosi
malign
cell
shown
enhanc
innat
immun
respons
dsrna
effect
compon
improv
method
treat
prevent
infecti
cancer
diseas
use
dsrna
correct
patholog
process
differ
origin
discuss
recognit
viral
nucleic
acid
induct
interferon
synthesi
main
compon
innat
antivir
immun
gener
accept
doublestrand
rna
dsrna
one
import
mediat
interferon
ifn
induct
respons
viral
infect
viral
infect
associ
appear
cell
doublestrand
form
rna
either
repres
actual
viral
genom
viru
appear
viral
reproduct
cycl
primari
cascad
bodi
respons
viral
infect
administr
exogen
dsrna
recognit
initi
intracellular
signal
pathway
share
mani
similar
therefor
dsrna
may
consid
regul
antivir
reaction
howev
subsequ
studi
mechan
dsrna
action
shown
function
divers
regard
constant
interest
dsrna
substanc
creation
new
drug
prevent
treatment
infecti
noninfecti
diseas
wane
mani
year
review
summar
current
trend
pharmaceut
develop
drug
base
highpolymer
dsrna
note
unlik
situat
field
first
dsrna
prepar
obtain
character
much
known
interact
dsrna
cell
intracellular
signal
transduct
found
recognit
exogenousextracellular
dsrna
intracellular
space
perform
use
two
main
sensor
system
one
sensor
system
includ
receptor
wellstudi
famili
tolllik
receptor
type
tolllik
receptor
sensor
system
includ
cytoplasm
sensor
riglik
receptor
famili
rlr
type
system
abl
induc
product
type
interferon
proinflammatori
cytokin
pathway
activ
differ
human
type
transmembran
receptor
molecular
mass
kda
sever
structur
domain
extracellular
ectodomain
ecd
transmembran
domain
cytoplasm
signal
domain
structur
basi
interact
dsrna
extracellular
variabl
domain
ectodomain
horsesho
shape
contain
nand
ctermin
leucinerich
repeat
domain
lrr
transmembran
domain
consist
singl
alpha
helix
cytoplasm
signal
domain
contain
highli
conserv
sequenc
approxim
residu
homolog
intracellular
domain
receptor
therefor
call
receptor
tir
domain
signal
domain
involv
interact
activ
receptor
adapt
compon
intracellular
signal
pathway
inact
state
monom
activ
occur
result
dimer
respons
dsrna
bind
crystal
structur
analysi
complex
consist
two
ecd
dsrna
shown
ectodomain
bind
dsrna
molecul
two
nonglycosyl
site
locat
opposit
end
horsesho
despit
fact
receptor
ectodomain
bind
dsrna
rather
weak
dimer
complex
highli
stabl
due
intermolecular
contact
ecd
ctermin
domain
found
dimer
correspond
signal
induc
dsrna
least
base
pair
bp
correspond
minimum
spatial
possibl
distanc
site
dsrna
bind
receptor
ectodomain
monom
featur
provid
receptor
recognit
long
dsrna
appear
cell
result
viral
infect
shorter
polyribonucleotid
trna
rrna
microrna
abl
form
stabl
complex
ecd
second
characterist
featur
consist
receptor
bind
ligand
occur
via
surfac
interact
hydrogen
bond
electrostat
interact
sugarphosph
backbon
rna
individu
nucleotid
base
depend
secondari
structur
rna
explain
univers
ligandreceptor
interact
abil
receptor
bind
dsrna
differ
primari
structur
hand
evid
recogn
specif
ligand
characterist
presenc
absenc
hydroxyl
group
discrimin
dsrna
dna
molecul
express
mainli
special
cell
immun
system
macrophag
dendrit
cell
dc
receptor
also
found
somat
cell
cell
type
locat
insid
cell
compartmentson
membran
endosom
lysosom
although
cell
epitheli
cell
fibroblast
also
express
plasma
membran
outer
surfac
endocytosi
dsrnacontain
materi
intracellular
abl
move
mean
protein
endoplasm
reticulum
endosom
acquir
function
abil
ligand
recognit
regardless
receptor
local
bind
dsrna
accompani
receptor
phosphoryl
interact
trif
adapt
protein
provid
signal
transduct
form
intermedi
complex
regulatori
protein
first
signal
pathway
second
signal
way
fig
case
first
signal
pathway
bind
tank
relat
peptid
sintbad
turn
interact
andor
kinas
activ
kinas
phosphoryl
ifnregul
factor
nucleu
phosphoryl
irf
bind
region
ifn
promot
factor
result
attract
cofactor
rna
polymeras
ii
initi
interferon
gene
transcript
induct
due
dsrna
interact
second
signal
pathway
via
regulatori
molecul
lead
increas
activ
transcript
factor
nfkb
fig
caus
product
ifn
number
proinflammatori
cytokin
involv
induct
regul
wide
rang
immun
respons
interferon
turn
induc
express
gene
encod
protein
involv
realiz
antivir
respons
among
ifnstimul
gene
gene
encod
synthetasernas
l
oasrnas
l
enzym
caus
degrad
newli
synthes
cell
mrna
includ
viral
one
also
gene
encod
protein
kinas
r
pkr
inhibit
protein
synthesi
cell
synthes
pkr
constitut
interferon
increas
transcript
activ
gene
severalfold
mechan
activ
oasrnas
l
pkr
well
biolog
effect
studi
detail
protein
kinas
r
dsrnadepend
ifninduc
serthr
protein
kinas
nonphosphoryl
state
pkr
associ
ribosom
small
part
pkr
present
nucleu
key
step
pkr
activ
dsrna
bind
two
structur
similar
ntermin
motif
enzym
molecul
follow
subsequ
pkr
autophosphoryl
activ
pkr
phosphoryl
number
protein
includ
alpha
subunit
eukaryot
initi
factor
import
consequ
cell
cycl
phosphoryl
bind
thu
caus
inhibit
catalyz
reaction
protein
synthesi
fig
addit
pkr
activ
dsrna
inhibit
prolifer
variou
cell
type
induc
apoptosi
synthetaseribonucleas
l
l
oa
like
pkr
ifninduc
enzym
activ
depend
presenc
dsrna
cell
unlik
pkr
oa
separ
domain
bind
induc
dsrna
bind
region
posit
charg
groov
enzym
conform
chang
groov
oa
activ
center
becom
spatial
access
activ
enzym
danilenko
et
al
catalyz
atp
polymer
result
format
short
mono
di
tri
tetraoligoadenyl
interact
rnase
l
rnase
l
transform
inact
monomer
form
activ
dimer
fig
rnase
l
protein
molecular
mass
kda
consist
three
domain
ntermin
regulatori
domain
contain
nine
ankyrinlik
region
protein
kinaselik
domain
ctermin
rnase
domain
oligom
interact
ankyrinlik
site
rnase
l
ntermin
domain
complex
format
accompani
conform
chang
lead
dimer
enzym
molecul
ctermin
ribonucleas
domain
becom
catalyt
activ
destroy
mrna
fragment
rnase
l
suppress
format
complet
viral
rna
lead
inhibit
protein
synthesi
assembl
viral
particl
thu
oa
pkr
dsrnadepend
enzym
becom
activ
presenc
dsrna
fact
indic
import
role
dsrna
marker
viral
infect
trigger
intracellular
antivir
reaction
factor
alreadi
mention
addit
present
almost
cell
type
anoth
fig
induct
cell
signal
pathway
respons
exposur
dsrna
bind
extracellular
dsrna
dsrna
absorb
endocytosi
phagocytosi
lead
receptor
phosphoryl
bind
adapt
molecul
trif
serv
platform
assembl
protein
involv
trigger
signal
pathway
lead
activ
case
signal
pathway
activ
trif
interact
oligomer
latter
acquir
activ
caus
ubiquitin
protein
polyubiquitin
sequenc
recogn
protein
promot
kinas
bind
complex
attach
ubiquitin
molecul
recogn
nemo
result
ikk
complex
bind
complex
phosphoryl
ikkb
subunit
ikk
complex
promot
activ
phosphoryl
ikb
bind
ubiquitin
undergo
proteasom
degrad
releas
migrat
nucleu
bind
promot
activ
pathway
bind
tank
sintbad
peptid
turn
interact
andor
activ
form
abl
phosphoryl
activ
factor
occur
similarli
nucleu
activ
irf
bind
region
promot
result
involv
cofactor
rna
polymeras
ii
initi
transcript
abbrevi
triftollinterleukin
il
tir
domaincontain
adaptor
induc
irfinterferon
regulatori
factor
factor
nuclear
factor
kappalightchainenhanc
activ
b
cell
receptorassoci
factor
protein
essenti
modifi
ikkinhibitor
nuclear
factor
kinas
growth
factor
kinas
adapt
dsrna
sensor
system
belong
famili
riglik
receptor
rlr
complex
protein
wellorgan
signal
function
domain
characterist
autoinhibit
mechan
protein
retino
acidinduc
gene
melanoma
differentiationassoci
gene
contain
ctermin
rna
recognit
domain
central
dexdh
helicoid
domain
two
ntermin
card
domain
caspas
activ
recruit
domain
abl
bind
cardcontain
adapt
adapt
protein
turn
serv
platform
assembl
signal
protein
trigger
pathway
fig
specif
dsrna
recognit
individu
sensor
famili
exampl
recogn
singlestrand
rna
doublestrand
compon
contain
termin
well
rel
short
nucleotid
dsrna
form
due
action
activ
rnase
l
sinc
partial
complementari
sequenc
domain
contain
dsrna
triphosph
characterist
panhandl
structurea
doublestrand
fragment
negativestrand
rna
viru
genom
mechan
seem
provid
recognit
specif
dsrna
virus
influenza
rabi
measl
given
sensori
molecul
contrast
recogn
rel
long
kb
dsrna
therefor
sensor
type
virus
particularli
encephalomyocard
viru
suggest
domin
cytoplasm
receptor
complex
polyinosin
polycytidyl
acid
polyi
polyc
recent
helicas
laboratori
genet
physiolog
consid
exclus
inhibit
factor
famili
prevent
bind
activ
howev
sever
research
group
shown
posit
regul
rlrinduc
signal
ribosom
activ
danilenko
et
al
increas
recognit
effici
viral
dsrna
recent
found
addit
describ
receptor
system
system
intracellular
sensor
signal
molecul
interact
dsrna
cell
specif
featur
ligand
bind
biolog
role
system
yet
fulli
understood
includ
famili
nlr
nodlik
receptor
nucleotidebind
oligomer
domainlik
receptor
nlr
local
intracellularli
express
mani
cell
type
immunocyt
epitheli
cell
induct
apoptosi
influenza
infect
associ
nod
receptor
extracellular
dsrna
receptorssra
scaveng
class
receptor
respons
dsrna
penetr
cell
interact
intracellular
sensor
synthesi
type
ifn
thu
realiz
dsrna
effect
cell
involv
sever
receptor
system
specif
term
dsrna
recognit
receptor
divers
provid
reliabl
identif
foreign
doublestrand
structur
differenti
endogen
cell
rna
final
induct
intracellular
signal
pathway
lead
express
cytokin
gene
primarili
ifn
activ
dsrnabind
enzym
key
element
antivir
respons
abil
dsrna
induc
synthesi
ifn
cytokin
basi
divers
immunomodulatori
properti
shown
dsrna
caus
increas
absorpt
metabol
bactericid
activ
phagocyt
cell
macrophag
neutrophil
activ
natur
killer
nk
matur
activ
dc
lead
activ
cell
thu
dsrna
play
role
function
linker
innat
acquir
immun
system
provid
fast
product
defens
respons
infecti
challeng
anoth
import
aspect
dsrna
effect
cell
regul
cell
prolifer
apoptosi
current
known
apoptosi
infect
cell
occur
differ
dsrnadepend
pathway
activ
main
mechan
implement
activ
caspas
describ
effect
dsrna
realiz
infect
cell
also
cell
subject
malign
transform
shown
sever
mous
human
cell
line
agonist
inhibit
growth
tumor
cell
two
main
mechan
suppress
prolifer
induct
apoptot
death
addit
dsrna
abl
influenc
immun
system
cell
induc
antitumor
immun
respons
stimul
antigenpres
dc
dsrna
lead
activ
nk
cell
cytotox
tlymphocyt
caus
death
tumor
cell
phenotyp
transform
myeloid
suppressor
cell
tumorassoci
macrophag
caus
dsrna
result
increas
antitumor
activ
thu
agonist
sever
type
intracellular
receptor
sensor
respons
emerg
respons
system
dsrna
perform
import
function
activ
clinic
use
exogen
dsrna
direct
use
evolutionarili
form
mechan
induct
activ
cytokin
enzym
cellular
protein
involv
develop
antivir
antitumor
reaction
therapeut
purpos
dsrna
drug
substanc
high
polymer
dsrna
attract
term
therapeut
potenti
subdivid
two
type
natur
synthet
sourc
natur
dsrna
addit
rnacontain
virus
caus
diseas
human
anim
insect
virus
plant
microorgan
virus
fungi
contain
dsrna
element
basi
type
dsrna
ridostin
larifan
prepar
develop
approv
use
clinic
practic
ridostin
drug
base
dsrna
isol
viruslik
particl
saccharomyc
cerevisia
killer
strain
two
individu
form
l
kb
kb
respect
develop
src
vb
vector
russia
ridostin
highli
effect
antivir
agent
ifn
induc
immunomodul
use
treat
influenza
herp
chlamydia
infect
certain
evid
exist
ridostin
increas
effect
antitumor
therapi
larifan
produc
larifan
ltd
latvia
drug
contain
replic
form
bacteriophag
dsrna
obtain
escherichia
coli
cell
infect
phage
base
phage
dsrna
sever
dosag
form
develop
inject
form
larifan
antivir
immunostimulatori
drug
antitumor
activ
larifan
ointment
suppositori
limit
inform
exist
develop
drug
base
natur
dsrna
one
exampl
dsrna
bacteriophag
isol
infect
pseudomona
phaseolicola
cell
repres
mixtur
dsrna
differ
length
kb
kb
kb
l
mand
sform
respect
seri
experiment
studi
shown
phage
dsrna
exhibit
high
ifninduc
antivir
activ
virus
caus
omsk
hemorrhag
fever
influenza
viru
synthet
dsrna
anoth
type
high
polymer
dsrna
wide
use
pharmaceut
develop
histori
synthet
doublestrand
polyribonucleotid
complex
began
grunbergmanago
ochoa
show
enzym
polynucleotid
phosphorylas
pnpase
ec
azotobact
vinelandii
presenc
mg
could
catalyz
reaction
polynucleotid
synthesi
certain
structur
kb
ribonucleosid
diphosph
releas
stoichiometr
amount
orthophosph
subsequ
doublestrand
complex
obtain
complementari
polyribonucleotid
anneal
develop
simpl
method
synthesi
highpolym
dsrna
open
possibl
produc
suffici
quantiti
studi
creat
drug
basi
seri
studi
vilner
et
al
shown
antivir
activ
synthet
polyribonucleotid
significantli
depend
polym
length
clear
determin
specif
receptor
bind
base
result
biolog
studi
polya
polyu
polyg
polyc
polyi
polyc
exhibit
pronounc
ifninduc
antivir
activ
chosen
studi
shown
vitro
vivo
experi
polya
polyu
suppress
reproduct
herp
virus
virus
reproduct
respiratori
syndrom
transmiss
gastroenter
african
swine
fever
activ
ifn
induc
although
abil
enhanc
interferon
synthesi
increas
surviv
mice
experiment
viral
infect
bit
lower
polyg
polyc
polyi
polyc
current
basi
polya
polyu
drug
poludan
manufactur
lancefarm
llc
russia
develop
regist
use
form
eye
nasal
drop
viral
eye
diseas
adenovir
herpet
keratoconjunct
kerat
keratoiridocycl
etc
complex
therapi
influenza
acut
respiratori
infect
data
clinic
trial
foreign
drug
analogu
polyadenur
polya
polyu
molecular
mass
rang
kda
kda
develop
beaufour
ipsen
franc
togeth
hemispherx
biopharma
usa
use
compon
complex
therapi
combin
hepat
b
c
also
treatment
breast
cancer
accord
classif
propos
yershov
et
al
polyg
polyc
polyi
polyc
base
drug
refer
group
highli
activ
ifn
induc
ifn
titer
peak
respons
unitsml
pronounc
antivir
activ
studi
complex
doublestrand
polyriboguanyl
polyribocytidyl
acid
polyg
polyc
polyguacyl
perform
show
drug
broad
spectrum
antivir
activ
could
effect
acut
phase
viral
hepat
enceph
treatment
influenza
rabi
howev
number
signific
drawback
uncertainti
chemic
structur
lack
homogen
result
unpredict
pharmacokinet
toxic
polyguacyl
becam
seriou
obstacl
clinic
use
research
riboxx
gmbh
germani
develop
modifi
method
produc
polyg
polyc
overcom
drawback
new
drug
character
strictli
defin
length
bp
chemic
structur
good
solubl
pronounc
immunomodulatori
activ
particularli
abil
caus
dc
activ
tcell
prolifer
improv
result
appear
drug
gi
polyc
one
chain
polyc
complementari
chain
contain
g
random
quantit
combin
n
n
total
number
nucleotid
complementari
chain
pharmaceut
composit
contain
activ
compon
poli
gi
polyc
least
bp
length
combin
pharmaceut
accept
carrier
excipi
andor
solvent
accord
author
patent
poli
gi
polyc
use
activ
innat
immun
prevent
treatment
infecti
neoplast
diseas
interest
note
despit
compar
level
antivir
activ
less
pronounc
toxic
properti
polyg
polyc
complex
recent
creation
drug
base
complex
polyi
polyc
develop
intens
world
pharmaceut
practic
like
one
reason
prefer
consist
technolog
problem
obtain
polyg
although
reason
also
possibl
eg
differ
width
manifest
immunomodul
action
complex
studi
biolog
properti
polyi
polyc
start
show
drug
power
activ
innat
immun
induc
tumor
cell
apoptosi
promis
result
obtain
clinic
studi
polyi
polyc
mean
treat
season
influenza
well
treat
malign
tumor
differ
local
adult
children
improv
form
polyi
polyc
drug
ampligen
current
stage
clinic
trial
ampligen
polyi
polyc
u
doublestrand
complex
polyriboinosin
acid
copolym
cytidyl
uridyl
acid
c
u
ratio
length
bp
bp
hemispherx
biopharma
inc
usa
ifn
induc
markedli
reduc
incid
advers
effect
compar
parent
compound
clinicaltrialsgov
databas
type
clinic
trial
drug
regist
effect
drug
ampligen
demonstr
framework
combin
therapi
chronic
fatigu
syndrom
acquir
immu
danilenko
et
al
nodefici
syndrom
aid
current
drug
approv
argentina
treatment
sever
case
myalgic
encephalomyelitischron
fatigu
syndrom
improv
version
drug
ampligen
polyi
polyc
u
develop
contrast
ampligen
new
drug
character
higher
content
c
versu
u
therefor
reduc
abil
form
branch
dsrna
result
bind
activ
one
current
problem
associ
develop
product
synthet
polyribonucleotid
standard
structur
context
nakano
et
al
develop
new
method
product
industri
quantiti
polyi
polyc
strictli
defin
length
method
prevent
uncontrol
increas
length
polyribonucleotid
anneal
achiev
mix
sever
short
polyi
molecul
kb
one
long
polyc
molecul
kb
fig
use
method
possibl
obtain
prepar
given
length
character
higher
storag
stabil
compar
origin
polyi
polyc
word
natur
synthet
dsrna
prepar
alreadi
employ
clinic
practic
antivir
antitumor
therapeut
agent
among
modern
area
pharmaceut
develop
two
activ
develop
trend
recogn
improv
dsrna
dosag
form
increas
effect
activ
substanc
wider
use
widespread
clinic
use
dsrna
base
prepar
often
hamper
instabl
biolog
media
high
level
effect
dose
side
effect
numer
effort
undertaken
improv
dsrna
effici
particular
attent
paid
drug
formul
enhanc
action
main
substanc
reduc
side
effect
prepar
polymer
carrier
mean
target
deliveri
nucleic
acid
penetr
cell
improv
frequent
use
cation
polym
neg
charg
nucleic
acid
prevent
interact
neg
charg
cell
surfac
bind
nucleic
acid
polyc
neg
charg
neutral
reduc
size
promot
nucleic
acid
transfect
cell
known
prepar
dsrna
prepar
stabil
polym
hiltonol
hiltonol
polyi
polyc
stabil
poli
llysin
carboxymethylcellulosepoli
iclc
develop
oncovir
inc
usa
poli
iclc
character
increas
resist
hydrolysi
induc
ifn
synthesi
thu
exhibit
modul
effect
immun
system
cell
includ
activ
tcell
nk
cell
dc
synthesi
cytokin
interleukin
corticosteroid
less
toxic
exist
analog
use
higher
dose
treatment
patient
advanc
inoper
cancer
clinicaltrialsgov
databas
contain
inform
clinic
trial
hiltonol
treatment
oncolog
diseas
variou
local
influenza
sever
acut
respiratori
syndrom
sar
viral
diseas
hiltonol
attract
potenti
drug
treatment
ebola
haemorrhag
fever
liposom
anoth
variant
cation
deliveri
vehicl
wong
et
al
show
intranas
administr
polyiclc
encapsul
cation
liposom
mice
prior
infect
lethal
dose
influenza
viru
provid
higher
level
protect
nonencapsul
drug
mice
infect
dengu
viru
polyiclc
encapsul
liposom
enhanc
antivir
reaction
mainli
increas
express
cytokin
particularli
liposom
conjug
antibodi
protein
ligand
provid
target
deliveri
exampl
liposom
contain
polyi
polyc
prepar
incorpor
sendai
polyc
control
length
viru
fusogen
f
protein
lipid
bilay
target
monoclon
antibodi
bound
liposom
via
staphylococcu
aureu
protein
immunoliposom
shown
provid
reason
level
polyi
polyc
intern
suffici
antivir
respons
induct
composit
contain
yeast
dsrna
activ
ingredi
drug
ridostin
polym
polyvinylpyrrolidon
exhibit
prolong
activ
effect
system
nonspecif
resist
reduc
toxic
initi
drug
recent
year
transport
system
base
polyethyleneimin
pei
activ
develop
nucleic
acid
deliveri
pei
polyplex
provid
higher
level
transfect
protect
rna
action
nucleas
compar
polyc
associ
high
densiti
charg
pei
contribut
condens
nucleic
acid
compact
complex
reduc
toxic
properti
pei
polyplex
modifi
peg
studi
construct
contain
polyi
polyc
epiderm
growth
factor
show
high
concentr
immobil
dsrna
accumul
tumor
tissu
caus
regress
glioblastoma
adenocarcinoma
breast
cancer
polysaccharid
wide
use
pharmacolog
particularli
encapsul
matrix
prepar
drug
formul
base
yeast
dsrna
polyglucin
dextran
molecular
mass
kda
ridostin
fort
earlytyp
ifn
induc
character
high
ifninduc
antivir
activ
creat
chitosan
anoth
polysaccharid
wide
use
creation
drug
dosag
formul
due
low
toxic
high
sorption
capac
bactericid
activ
biocompat
biodegrad
use
bisphosphon
synthet
analogu
natur
pyrophosph
interest
aspect
context
develop
method
drug
deliveri
bone
bisphosphon
bp
character
high
affin
apatit
bone
structur
also
antitumor
activ
order
provid
intracellular
codeliveri
polyi
polyc
thirdgener
bisphosphon
zoledron
acid
zol
chen
et
al
obtain
lipid
coat
calcium
phosphat
nanoparticl
lcp
shown
lcp
load
polyi
polyc
zol
exhibit
significantli
higher
antitumor
activ
melanoma
cell
free
polyi
polyc
zol
prepar
synerg
antitumor
action
polyi
polyc
zol
lcp
composit
also
demonstr
mice
transplant
melanoma
dsrna
deliveri
system
also
develop
basi
inorgan
molecul
exampl
iron
oxid
nanoparticl
use
polyi
polyc
deliveri
lymph
node
led
signific
increas
immun
respons
immun
mice
calcium
phosphat
particl
contain
polyi
polyc
cpg
dinucleotid
promot
intens
uptak
dc
accompani
expans
pathogenspecif
tlymphocyt
anoth
way
improv
therapeut
characterist
dsrna
develop
dosag
form
indent
nonparenter
use
especi
attract
case
treatment
infecti
diseas
mucou
membran
gateway
infect
mcnalli
et
al
demonstr
singl
intranas
administr
polyi
polyc
mice
induc
local
product
chemokin
lung
upper
respiratori
tract
gener
steadi
migrat
tlymphocyt
respiratori
tract
observ
effect
depend
length
dsrna
author
anoth
studi
found
intranas
administr
liposom
polyiclc
shortli
infect
mice
influenza
viru
inhibit
viral
replic
result
decreas
lung
titer
increas
level
specif
humor
cellular
immun
respons
surviv
infect
anim
addit
liposom
polyiclc
prevent
develop
pulmonari
fibrosi
seriou
complic
infect
experiment
clinic
studi
shown
dsrna
use
adjuv
modul
optim
antigenspecif
immun
respons
evalu
paramet
innat
immun
respons
administr
polyi
polyc
stabil
poli
llysin
carboxymethylcellulos
polyiclc
volunt
show
administr
drug
caus
format
immun
reaction
similar
observ
immun
yellow
fever
vaccin
therefor
drug
could
use
enhanc
vaccin
immunogen
martin
et
al
studi
effect
polyiclc
efficaci
vaccin
mice
guinea
pig
primat
viruslik
particl
vlp
filoviru
administr
polyiclc
result
increas
level
chemokin
activ
dc
nk
bcell
drug
enhanc
antigenspecif
tcell
respons
increas
product
antibodi
protect
viral
infect
coadministr
polyi
polyc
lipoteicho
acid
ligand
imidazoquinolin
compound
high
antivir
activ
inactiv
vaccin
porcin
reproduct
respiratori
syndrom
viru
prrsv
confer
higher
protect
infect
increas
cellular
immun
respons
found
guinea
pig
danilenko
et
al
immun
vlp
vaccin
fmd
viru
combin
polyi
polyc
reliabl
protect
mice
tickborn
enceph
viru
observ
vaccin
specif
inactiv
tickborn
enceph
vaccin
encevir
combin
drug
ridostin
ridostin
also
increas
protect
properti
weakli
immunogen
vaccin
tuberculosi
hors
strangl
diseas
design
microcarri
deliveri
antigen
combin
immunoadjuv
antigenpres
cell
apc
one
activ
develop
area
vaccin
construct
ligand
particularli
polyi
polyc
also
use
candid
adjuv
system
adjuv
activ
profession
apc
dc
macrophag
also
nonimmun
cell
epitheli
cell
endotheli
cell
fibroblast
result
develop
autoimmun
reaction
chronic
inflamm
order
avoid
undesir
reaction
hafner
et
al
propos
origin
polyi
polyc
deliveri
system
microcarri
neg
charg
polystyren
microspher
equip
crown
polyethylen
glycol
peg
form
electrostat
coat
polycation
copolym
base
poli
llysin
graftpoli
ethylen
glycol
experi
primari
cultur
peripher
blood
monocyt
shown
polyi
polyc
adsorb
surfac
microspher
caus
activ
monocytederiv
dc
time
prepar
drug
affect
express
antigen
major
histocompat
complex
mhc
class
secret
human
skin
fibroblast
weaken
phagocyt
activ
indic
adsorb
polyi
polyc
lack
abil
induc
advers
inflammatori
reaction
use
nonparenter
rout
administr
dsrna
adjuv
particular
interest
exampl
mucos
treatment
polyi
polyc
shortli
vaccin
mice
live
attenu
influenza
vaccin
enhanc
function
activ
respiratori
tract
dc
format
tcell
product
neutral
antibodi
kim
et
al
found
increas
product
antigenspecif
serum
igg
mucos
iga
respons
vaccin
mice
trival
hemagglutininsubunit
split
vaccin
antigen
administr
polyi
polyc
eyedrop
adjuv
importantli
increas
mrna
express
proinflammatori
cytokin
mononuclear
cell
infiltr
inject
site
indic
drug
side
effect
form
local
inflammatori
respons
uchida
et
al
develop
origin
platform
improv
mrna
vaccin
base
follow
eukaryot
mrna
polya
tail
form
result
mrna
process
hybrid
polyu
hybrid
affect
effici
mrna
translat
doublestrand
portion
mrna
polyu
immunostimul
effect
activ
mous
human
dendrit
cell
mrna
polyu
time
effici
case
singlestrand
mrna
studi
immunostimul
mechan
perform
cell
cultur
character
high
level
express
character
receptor
knockout
show
immun
respons
mrna
hybrid
polyu
mediat
rigi
thu
use
dsrna
vaccin
adjuv
make
possibl
increas
protect
adjuv
activ
dsrna
seem
base
abil
alter
balanc
cytokin
modul
activ
cell
mediat
specif
nonspecif
immun
respons
although
first
identifi
cell
immun
system
recent
studi
shown
also
express
malign
cell
antitumor
effect
agonist
polyi
polyc
demonstr
wide
rang
mous
human
tumor
cell
line
exampl
evid
intracellular
deliveri
liposom
polyi
polyc
human
ag
adenocarcinoma
cell
induc
tumor
cell
apoptosi
vitro
significantli
inhibit
xenograft
growth
nude
mice
similar
result
obtain
chen
et
al
show
transfect
polyi
polyc
hela
cervic
cancer
cell
induc
synthesi
format
reactiv
oxygen
speci
caus
dna
damag
activ
caspas
final
apoptosi
antiprolif
cytotox
apoptogen
effect
polyi
polyc
observ
experi
poorli
differenti
human
urinari
bladder
cancer
cell
line
cell
drug
induc
growth
arrest
transit
also
increas
immunogen
cell
induc
express
mhc
class
molecul
surfac
secret
proinflammatori
cytokin
abil
polyi
polyc
induc
apoptosi
prostat
cancer
cell
demonstr
cell
line
deriv
bone
intracerebr
metastas
human
tumor
effect
pronounc
androgendepend
lncap
line
apoptogen
effect
polyi
polyc
also
report
tumor
histotyp
eg
tumor
breast
head
neck
kidney
colon
lung
studi
perform
cell
human
melanoma
section
materi
shown
apoptogen
effect
dsrna
enhanc
combin
use
cytokin
despit
exist
intrins
antitumor
activ
dsrna
prepar
frequent
studi
synergist
adjuv
enhanc
action
specif
therapeut
agent
vaccin
exampl
ayari
et
al
shown
combin
polyi
polyc
bacillu
bcg
vaccin
enhanc
antitumor
effect
bcg
bladder
cancer
transplant
mice
similar
result
obtain
muthuswami
et
al
author
believ
combin
use
bcg
polyi
polyc
may
new
method
increas
effect
immunotherapi
bladder
cancer
alipour
et
al
develop
polyi
polyc
deliveri
system
enhanc
antitumor
immun
respons
peptid
contain
multipl
epitop
glycopeptid
characterist
tumor
cell
peptid
encapsul
cation
nanoliposom
consist
modifi
cholesterol
contain
contain
polyi
polyc
group
mice
immun
liposom
carri
protein
polyi
polyc
well
liposom
contain
polyi
polyc
signific
level
secret
splenocyt
increas
number
tcell
compar
group
observ
pronounc
inhibit
growth
experiment
tubo
tumor
high
level
express
whole
experi
day
observ
treatment
liposom
contain
polyi
polyc
suggest
combin
polyi
polyc
liposom
tumor
antigen
abl
induc
antitumor
immun
respons
even
without
use
addit
thelper
epitop
intratumor
administr
plasmid
carri
apoptin
gene
polyi
polyc
significantli
inhibit
growth
mammari
tumor
balbc
mice
also
induc
potent
antitumor
immun
respons
evidenc
increas
number
tlymphocyt
increas
secret
cytokin
circul
tumor
tissu
infiltr
immun
cell
similar
data
obtain
use
polyi
polyc
togeth
canin
parvoviru
protein
common
solid
tumor
mani
hemoblastos
lymphoma
leukemia
multipl
myeloma
known
express
glycopeptid
howev
fulli
synthet
glycopeptid
tumor
vaccin
creat
basi
glycopeptid
character
low
immunogen
glaffig
et
al
found
use
polyi
polyc
adjuv
result
signific
increas
respons
vaccin
product
specif
igg
activ
interact
human
breast
tumor
cell
express
induct
cellular
immun
respons
kano
et
al
investig
polyi
polyc
recombin
protein
encod
lymphocyt
activ
gene
fuse
human
igg
fc
adjuv
peptid
vaccin
tumor
antigen
protein
express
membran
activ
bcell
plasmacytoid
dc
play
import
role
function
mice
graft
mastocytoma
tumor
polyi
polyc
combin
caus
reject
graft
tumor
increas
longev
anim
antitumor
effect
due
increas
prolifer
infiltr
tumor
tissu
tcell
product
cytokin
combin
polyi
polyc
suppress
express
number
protein
receptor
tcell
prevent
deplet
import
realiz
deep
longlast
antitumor
immun
respons
dc
dysfunct
seriou
obstacl
develop
effect
antitumor
vaccin
cell
often
use
vaccin
prepar
found
tumor
associ
dc
tadc
less
matur
normal
dc
respond
poorli
stimul
tlr
agonist
associ
possibl
hyperact
intracellular
order
overcom
dc
dysfunct
luo
et
al
develop
pmpovasirna
nanovaccin
polypeptid
micel
form
poli
ethyleneglycol
bpoli
llysin
bpoli
lleucin
hybrid
polypeptid
pegpllplleu
encapsul
ova
antigen
polyi
polyc
experi
shown
signific
increas
uptak
ova
antigen
sirna
tadc
administr
vaccin
decreas
express
pmpovasirna
vaccin
increas
express
marker
product
dc
exert
increas
number
matur
dc
decreas
number
immunosuppress
cell
lymph
node
ultim
contribut
weaken
immunosuppress
tumor
microenviron
develop
antitumor
immun
respons
tumor
regress
word
combin
immunomodul
polyi
polyc
nanovaccin
promis
strategi
increas
therapeut
efficaci
consid
literatur
data
indic
dsrna
compon
evolutionarili
form
system
nonspecif
protect
play
role
function
linker
innat
acquir
immun
system
synthet
natur
dsrna
preparadanilenko
et
al
tion
use
clinic
practic
pharmaceut
substanc
develop
prophylact
antivir
immunomodulatori
agent
clear
interest
expand
sphere
applic
method
improv
therapeut
properti
tabl
result
preclin
clinic
trial
experiment
studi
reveal
dsrna
exhibit
inhibitori
action
wide
rang
virus
well
adjuv
properti
demonstr
relat
vaccin
variou
viral
infect
modern
trend
pharmaceut
develop
includ
improv
dosag
form
dsrna
develop
target
deliveri
tool
improv
antivir
efficaci
improv
therapeut
properti
drug
rel
new
research
direct
includ
use
dsrna
antitumor
agent
antitumor
vaccin
adjuv
found
hat
drug
inhibit
growth
tumor
cell
prolifer
suppress
induct
apoptot
cell
death
enhanc
antitumor
immun
respons
current
clinic
trial
aim
investig
antitumor
properti
dsrna
drug
monoand
complex
therapi
combin
antitumor
agent
includ
vaccin
studi
mechan
action
role
dsrna
correct
patholog
process
variou
origin
obvious
help
optim
method
drug
usag
increas
effect
safeti
fund
review
prepar
within
framework
state
task
src
vb
vector
